Active Surveillance for Prostate Cancer Tripled Since 2005

The use of active surveillance for men diagnosed with low- and favorable intermediate-risk prostate cancer has more than tripled since 2005, according to a comprehensive study analyzing data from a large cohort of U.S. veterans. In 2005, active surveillance represented 27% of management strategies for men with low-risk prostate cancer. By 2010, this figure had risen to 44%. The trend continued upward, with active surveillance accounting for 62% of cases by 2015 and reaching 73% in 2020. This significant increase indicates a growing preference among clinicians and patients for monitoring the disease rather than immediately pursuing aggressive treatments like surgery or radiation, particularly for cancers deemed less likely to progress rapidly.

This shift in practice is particularly notable for favorable intermediate-risk prostate cancer. In 2005, only 11% of these patients were managed with active surveillance. This proportion grew to 23% by 2010, then to 37% by 2015. By 2020, active surveillance was employed in 51% of favorable intermediate-risk cases. The study, published in JAMA Oncology, highlights a substantial change in how prostate cancer is managed, reflecting evolving clinical understanding of disease progression and the potential harms associated with overtreatment. Active surveillance involves regular monitoring of the cancer through prostate-specific antigen (PSA) blood tests, digital rectal exams, and periodic biopsies, with treatment initiated only if there are signs of progression.

The research team, led by investigators from the University of Michigan, analyzed data from the Veterans Health Administration, a system that provides a large and diverse patient population for epidemiological studies. The study's findings suggest that the adoption of active surveillance has become a dominant strategy for managing low-risk prostate cancer and a significant option for favorable intermediate-risk disease. This trend aligns with broader discussions in oncology regarding de-escalation of care for indolent cancers to minimize side effects and improve quality of life for patients. The study did not specify the exact number of veterans included but described it as a "large study," implying a statistically robust dataset. The implications of this trend extend to healthcare resource utilization and patient outcomes, as active surveillance is generally less costly and less invasive than definitive treatments.

While the study demonstrates a clear increase in active surveillance, it does not delve into the specific reasons for this adoption across all healthcare settings or patient demographics within the veteran population. However, the consistent upward trajectory observed over 15 years points to a fundamental change in clinical philosophy and patient acceptance. The favorable intermediate-risk category, in particular, represents a group where the decision between active surveillance and immediate treatment can be complex, and the increasing reliance on surveillance suggests a greater comfort level with managing these cancers expectantly. Further research may explore the long-term oncological and quality-of-life outcomes associated with this widespread adoption of active surveillance.